| Fri, 07 Dec 2018 13:43:56: | DiaMedica pulls off IPO to fund midphase stroke trial
|
| Fri, 07 Dec 2018 11:53:54: | Moderna’s cash juggernaut rolls on with record $604M IPO
|
| Fri, 07 Dec 2018 11:04:27: | AstraZeneca’s tremelimumab fails another phase 3 cancer trial
|
| Thu, 06 Dec 2018 23:18:22: | Chutes & Ladders—Xenotransplantation firm eGenesis hires new R&D head
|
| Thu, 06 Dec 2018 15:32:45: | Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812
|
| Thu, 06 Dec 2018 13:51:16: | Genfit’s elafibranor hits goal in phase 2 PBC trial
|
| Thu, 06 Dec 2018 13:24:43: | Impel raises $67.5M as it eyes filing for nasal migraine drug
|
| Thu, 06 Dec 2018 13:10:48: | Midphase failure of Novartis’ NASH drug crushes Conatus
|
| Thu, 06 Dec 2018 11:48:33: | Regenerating insulin-producing cells with zinc could tackle the underlying cause of diabetes
|
| Wed, 05 Dec 2018 20:34:38: | Xenotransplantation firm eGenesis hires Wes Westlin as R&D head
|
| Wed, 05 Dec 2018 15:40:37: | Could blocking a single gene cure obesity without diet and exercise?
|
| Wed, 05 Dec 2018 14:09:31: | U.K. sets out digital, data-driven plan to accelerate R&D
|
| Wed, 05 Dec 2018 14:01:26: | ASH18: Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field
|
| Wed, 05 Dec 2018 13:27:34: | UCB to spend £200M to create U.K. R&D hub
|
| Tue, 04 Dec 2018 17:45:12: | Relay adds executives to its chemistry, R&D teams as it transitions to the development stage
|
| Tue, 04 Dec 2018 14:41:06: | SmartZyme spins off protein tech company for a metabolic disease partnership with Hemoshear
|
| Tue, 04 Dec 2018 13:44:29: | With Gilead and rivals deep in phase 3, FDA unveils draft guidance on NASH drug development
|
| Tue, 04 Dec 2018 13:36:17: | Boehringer inks pact with Domain for GPCR neurology drugs
|
| Tue, 04 Dec 2018 12:01:24: | ASH18: Amgen’s anti-BCMA bispecific shines again, but CAR-T threat remains
|
| Mon, 03 Dec 2018 16:22:40: | Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders
|
| Mon, 03 Dec 2018 14:16:52: | Regeneron records 80% complete response rate in lymphoma trial
|
| Mon, 03 Dec 2018 13:26:25: | ASH18: New data can’t lift Bluebird Bio’s depressed shares
|
| Mon, 03 Dec 2018 09:55:47: | ASH18: J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab
|
| Fri, 30 Nov 2018 17:11:23: | Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH
|
| Fri, 30 Nov 2018 13:56:20: | Principia chalks up a win for its BTK autoimmune program
|
